TR200202326T2 - Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı - Google Patents

Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı

Info

Publication number
TR200202326T2
TR200202326T2 TR2002/02326T TR200202326T TR200202326T2 TR 200202326 T2 TR200202326 T2 TR 200202326T2 TR 2002/02326 T TR2002/02326 T TR 2002/02326T TR 200202326 T TR200202326 T TR 200202326T TR 200202326 T2 TR200202326 T2 TR 200202326T2
Authority
TR
Turkey
Prior art keywords
hypertrophy
bradycardias
treatment
disorders accompanied
myocardial disorders
Prior art date
Application number
TR2002/02326T
Other languages
English (en)
Turkish (tr)
Inventor
D�mmgen J�rgen
Guth Brian
Seidler Randolph
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of TR200202326T2 publication Critical patent/TR200202326T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2002/02326T 2000-04-13 2001-04-07 Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı TR200202326T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen

Publications (1)

Publication Number Publication Date
TR200202326T2 true TR200202326T2 (tr) 2003-03-21

Family

ID=7638652

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/02326T TR200202326T2 (tr) 2000-04-13 2001-04-07 Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı

Country Status (33)

Country Link
US (2) US7208508B2 (enExample)
EP (2) EP1276476B1 (enExample)
JP (1) JP3905386B2 (enExample)
KR (1) KR20020089453A (enExample)
CN (1) CN1245963C (enExample)
AT (1) ATE330588T1 (enExample)
AU (2) AU7048401A (enExample)
BG (1) BG65816B1 (enExample)
BR (1) BR0109996A (enExample)
CA (2) CA2575059A1 (enExample)
CY (1) CY1105081T1 (enExample)
CZ (1) CZ300549B6 (enExample)
DE (2) DE10018401A1 (enExample)
DK (1) DK1276476T3 (enExample)
EA (1) EA006977B1 (enExample)
EE (1) EE05099B1 (enExample)
ES (1) ES2266216T3 (enExample)
HR (1) HRP20020815A2 (enExample)
HU (1) HU228387B1 (enExample)
IL (2) IL152103A0 (enExample)
ME (1) MEP45908A (enExample)
MX (1) MXPA02009935A (enExample)
NO (1) NO330311B1 (enExample)
NZ (1) NZ521934A (enExample)
PL (1) PL215235B1 (enExample)
PT (1) PT1276476E (enExample)
RS (1) RS51478B (enExample)
SI (1) SI1276476T1 (enExample)
SK (1) SK286075B6 (enExample)
TR (1) TR200202326T2 (enExample)
UA (1) UA78679C2 (enExample)
WO (1) WO2001078699A2 (enExample)
ZA (1) ZA200208162B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
ATE257384T1 (de) * 2002-07-25 2004-01-15 Boehringer Ingelheim Pharma Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
RS20050590A (sr) * 2003-01-31 2007-09-21 Sankyo Company Limited, Lek za profilaksu i tretman arterioskleroze i hipertenzije
KR101384841B1 (ko) * 2005-06-27 2014-04-15 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를함유한 약학 제제
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
KR20140057604A (ko) * 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts
BR112020000194A2 (pt) 2017-07-07 2020-07-07 Boehringer Ingelheim Vetmedica Gmbh antagonista do receptor de angiotensina ii para a prevenção ou o tratamento de doenças sistêmicas em gatos
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3541811A1 (de) 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
EP0720616A1 (en) * 1993-09-24 1996-07-10 The Procter & Gamble Company Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
SI1096932T1 (sl) * 1998-07-10 2008-04-30 Novartis Pharma Ag Antihipertenzivna kombinacija valsartana in zaviralca kalcijevih kanalov
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
CZ20023752A3 (cs) 2003-03-12
SK14582002A3 (sk) 2003-03-04
UA78679C2 (en) 2007-04-25
EE05099B1 (et) 2008-12-15
CA2404120C (en) 2008-01-22
CA2404120A1 (en) 2001-10-25
HU228387B1 (en) 2013-03-28
HUP0300917A2 (hu) 2003-08-28
CA2575059A1 (en) 2001-10-25
PL357827A1 (en) 2004-07-26
EA006977B1 (ru) 2006-06-30
DE10018401A1 (de) 2001-10-25
AU7048401A (en) 2001-10-30
NO20024924L (no) 2002-10-11
IL152103A0 (en) 2003-07-31
WO2001078699A3 (de) 2002-06-20
CY1105081T1 (el) 2009-11-04
CZ300549B6 (cs) 2009-06-10
AU2001270484B2 (en) 2007-01-25
EP1276476B1 (de) 2006-06-21
EP1666042A3 (de) 2006-06-21
HUP0300917A3 (en) 2009-04-28
BG107103A (bg) 2003-04-30
NZ521934A (en) 2007-05-31
BR0109996A (pt) 2003-05-27
JP3905386B2 (ja) 2007-04-18
YU76902A (sh) 2006-05-25
SI1276476T1 (sl) 2006-10-31
DK1276476T3 (da) 2006-08-14
MEP45908A (en) 2011-02-10
US20070155679A1 (en) 2007-07-05
KR20020089453A (ko) 2002-11-29
ZA200208162B (en) 2003-10-17
BG65816B1 (bg) 2010-01-29
ATE330588T1 (de) 2006-07-15
PL215235B1 (pl) 2013-11-29
ES2266216T3 (es) 2007-03-01
EP1276476A2 (de) 2003-01-22
US7208508B2 (en) 2007-04-24
EA200201053A1 (ru) 2003-02-27
EE200200590A (et) 2004-04-15
JP2003535050A (ja) 2003-11-25
HRP20020815A2 (en) 2004-12-31
WO2001078699A2 (de) 2001-10-25
IL152103A (en) 2008-07-08
CN1245963C (zh) 2006-03-22
SK286075B6 (sk) 2008-03-05
NO330311B1 (no) 2011-03-28
US20040014795A1 (en) 2004-01-22
DE50110262D1 (de) 2006-08-03
PT1276476E (pt) 2006-09-29
RS51478B (sr) 2011-04-30
MXPA02009935A (es) 2003-02-12
NO20024924D0 (no) 2002-10-11
CN1422153A (zh) 2003-06-04
EP1666042A2 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
TR200202326T2 (tr) Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı
DE60220719D1 (de) Antikörper gegen das muc18-antigen
TR200201364T2 (tr) Yeni bileşikler.
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
EP1461061A4 (en) COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
TR200401871T4 (tr) Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması
ATE263563T1 (de) Mittel gegen juckreiz
PA8484801A1 (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña
TR200103104T2 (tr) Glukortikoid alıcı modülatörleri
BR0007864A (pt) Composto, e, uso de um composto
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
PE83999A1 (es) Azetidinas
EE05662B1 (et) Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
TR200002896T2 (tr) Kalsilitik Bileşimler
MXPA03011630A (es) Compuestos de amenoacetonitrilo para el control de endoparasitos.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR200103090T2 (tr) Integrın reseptör antagonistleri
UY26473A1 (es) Compuestos activos en el receptor de glucocorticoide
DK1223930T3 (da) Behandling af dyskinesi
BR0115364A (pt) Tratamento de disfunção sexual
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
ATE406880T1 (de) Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen